Equities Analysts Issue Forecasts for TNDM FY2029 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for Tandem Diabetes Care in a research report issued on Thursday, February 27th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will earn $0.73 per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.68) per share.

A number of other equities analysts have also recently issued reports on TNDM. Citigroup decreased their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Morgan Stanley upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective on the stock in a report on Monday, December 2nd. Robert W. Baird decreased their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a report on Thursday. Barclays boosted their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Finally, Sanford C. Bernstein cut Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $35.00 to $25.00 in a research report on Friday. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $52.31.

Tandem Diabetes Care Trading Down 35.2 %

Tandem Diabetes Care stock opened at $21.75 on Friday. Tandem Diabetes Care has a 1 year low of $21.43 and a 1 year high of $53.69. The firm’s 50 day moving average price is $35.22 and its two-hundred day moving average price is $36.52. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -11.27 and a beta of 1.32. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Brooklyn Investment Group acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at $28,000. Assetmark Inc. bought a new stake in Tandem Diabetes Care during the third quarter worth approximately $29,000. AlphaQuest LLC grew its holdings in Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 541 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after buying an additional 748 shares during the last quarter. Finally, McIlrath & Eck LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth $52,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.